{"id":6166,"date":"2022-06-15T10:42:38","date_gmt":"2022-06-15T08:42:38","guid":{"rendered":"https:\/\/www.rapharm.eu\/en\/?p=6166"},"modified":"2022-06-15T10:50:51","modified_gmt":"2022-06-15T08:50:51","slug":"eu-evaluation-of-cannabidiol-cbd-as-a-novel-food-suspended","status":"publish","type":"post","link":"https:\/\/www.rapharm.eu\/en\/eu-evaluation-of-cannabidiol-cbd-as-a-novel-food-suspended\/","title":{"rendered":"EU: Evaluation of cannabidiol (CBD) as a novel food suspended"},"content":{"rendered":"<style type=\"text\/css\"><\/style>\n<p>The European Food Safety Authority (EFSA)\ncurrently suspending the evaluation of CBD as a novel food, as current\nscientific documentation does not establish safety in the use of CBD in food,\nmainly due to lack of documentation, some ambiguities and potential risks\nassociated with CBD consumption.<\/p>\n\n\n\n<p>Chair of the NDA Panel, Prof.\nDominique Turck said that during the evaluation, some risks regarding the use\nof CBD were identified, which must be eliminated by supplementing the\nscientific documentation before continuing with the work. At the same time, he\nalso points out that this does not mean that they have concluded that CBD is as\ndangerous as food.<\/p>\n\n\n\n<p>The lack of documentation relates mainly to\nthe effects of CBD on the liver, digestive tract, endocrine and nervous\nsystems, and psychological well-being in humans.<\/p>\n\n\n\n<p><strong>Do you need additional knowledge\nor help in reviewing the suitability of ingredients and other product\nproperties before entering the market?<\/strong><\/p>\n\n\n\n<p>With the help of our <a href=\"https:\/\/www.rapharm.eu\/en\/consulting-services\/\">consulting services<\/a>, we can fully help you with\nthorough reviews of the suitability of products for entering the market, as\nwell as foreign markets and opportunities for legal marketing of food supplements.<\/p>\n\n\n\n<p>Resource:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.efsa.europa.eu\/en\/news\/cannabidiol-novel-food-evaluations-hold-pending-new-data\">Cannabidiol\nnovel food evaluations on hold pending new data | EFSA (europa.eu)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The European Food Safety Authority (EFSA) currently suspending the evaluation of CBD as a novel food, as current scientific documentation does not establish safety in the use of CBD in food, mainly due to lack of documentation, some ambiguities and potential risks associated with CBD consumption. Chair of the NDA Panel, Prof. Dominique Turck said&#8230;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45,30],"tags":[],"class_list":["post-6166","post","type-post","status-publish","format-standard","hentry","category-novice-en","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>EU: Evaluation of cannabidiol (CBD) as a novel food suspended - raPHARM<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EU: Evaluation of cannabidiol (CBD) as a novel food suspended - raPHARM\" \/>\n<meta property=\"og:description\" content=\"The European Food Safety Authority (EFSA) currently suspending the evaluation of CBD as a novel food, as current scientific documentation does not establish safety in the use of CBD in food, mainly due to lack of documentation, some ambiguities and potential risks associated with CBD consumption. Chair of the NDA Panel, Prof. Dominique Turck said...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/\" \/>\n<meta property=\"og:site_name\" content=\"raPHARM\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-15T08:42:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-15T08:50:51+00:00\" \/>\n<meta name=\"author\" content=\"rapharm\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rapharm\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/\",\"url\":\"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/\",\"name\":\"EU: Evaluation of cannabidiol (CBD) as a novel food suspended - raPHARM\",\"isPartOf\":{\"@id\":\"https:\/\/www.rapharm.eu\/#website\"},\"datePublished\":\"2022-06-15T08:42:38+00:00\",\"dateModified\":\"2022-06-15T08:50:51+00:00\",\"author\":{\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.rapharm.eu\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU: Evaluation of cannabidiol (CBD) as a novel food suspended\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rapharm.eu\/#website\",\"url\":\"https:\/\/www.rapharm.eu\/\",\"name\":\"raPHARM\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rapharm.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1\",\"name\":\"rapharm\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.rapharm.eu\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g\",\"caption\":\"rapharm\"},\"url\":\"https:\/\/www.rapharm.eu\/en\/author\/rapharm\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EU: Evaluation of cannabidiol (CBD) as a novel food suspended - raPHARM","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/","og_locale":"en_US","og_type":"article","og_title":"EU: Evaluation of cannabidiol (CBD) as a novel food suspended - raPHARM","og_description":"The European Food Safety Authority (EFSA) currently suspending the evaluation of CBD as a novel food, as current scientific documentation does not establish safety in the use of CBD in food, mainly due to lack of documentation, some ambiguities and potential risks associated with CBD consumption. Chair of the NDA Panel, Prof. Dominique Turck said...","og_url":"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/","og_site_name":"raPHARM","article_published_time":"2022-06-15T08:42:38+00:00","article_modified_time":"2022-06-15T08:50:51+00:00","author":"rapharm","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rapharm","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/","url":"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/","name":"EU: Evaluation of cannabidiol (CBD) as a novel food suspended - raPHARM","isPartOf":{"@id":"https:\/\/www.rapharm.eu\/#website"},"datePublished":"2022-06-15T08:42:38+00:00","dateModified":"2022-06-15T08:50:51+00:00","author":{"@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1"},"breadcrumb":{"@id":"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rapharm.eu\/evalvacija-kanabidiola-cbd-kot-novo-zivilo-zacasno-ustavljena\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rapharm.eu\/en\/"},{"@type":"ListItem","position":2,"name":"EU: Evaluation of cannabidiol (CBD) as a novel food suspended"}]},{"@type":"WebSite","@id":"https:\/\/www.rapharm.eu\/#website","url":"https:\/\/www.rapharm.eu\/","name":"raPHARM","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rapharm.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/ba2051c1c51d2328945ac838b3f1d7e1","name":"rapharm","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rapharm.eu\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9ea8e299db6979b3c68307fd37c34f245020d4996bcf2ccdeec4bce3350fcc24?s=96&d=mm&r=g","caption":"rapharm"},"url":"https:\/\/www.rapharm.eu\/en\/author\/rapharm\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts\/6166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/comments?post=6166"}],"version-history":[{"count":1,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts\/6166\/revisions"}],"predecessor-version":[{"id":6167,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/posts\/6166\/revisions\/6167"}],"wp:attachment":[{"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/media?parent=6166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/categories?post=6166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rapharm.eu\/en\/wp-json\/wp\/v2\/tags?post=6166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}